Journal of the Chinese Medical Association
Volume 73, Issue 5 , Pages 262-264 , May 2010

Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation

  • Murat Lekili

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • Corresponding Author InformationCorrespondence to: Dr Murat Lekili, Department of Urology, Celal Bayar University, School of Medicine, Uncubozköy Mevkii, Kat 8, Manisa, Turkey
    • ,
  • Talha Muezzinoglu

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • ,
  • Nalan Nese

      Affiliations

    • Department of Pathology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • ,
  • Gokhan Temeltas

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey

Received 16 April 2009 ,Accepted 3 March 2010.

References 

  1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al  Sorafenib in advanced clear cell renal cell carcinoma . N Engl J Med . 2007;356:125–134
  2. Motzer RJ, Hutson TE, Tomczak P, Michealson MD, Bukolwski RM, Rixe O, et al  Sunitinib versus interferon alfa in metastatic renal cell carcinoma . N Engl J Med . 2007;356:115–124
  3. Kroog GS , Motzer RJ . Systemic therapy for metastatic renal cell carcinoma . Urol Clin N Am . 2008;35:687–701
  4. Sciarra A, Gomez AA, Gentilucci A, Parente U, Salciccia S, Gentile V, et al. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report . Eur Urol . 2007;52:597–599

PII: S1726-4901(10)70056-3

doi: 10.1016/S1726-4901(10)70056-3

Journal of the Chinese Medical Association
Volume 73, Issue 5 , Pages 262-264 , May 2010

Article Tools